Ido Morpurgo - Purple Biotech VP Operations

PPBT Stock  ILA 7.40  0.50  6.33%   

Insider

Ido Morpurgo is VP Operations of Purple Biotech
Age 50
Phone972 3 933 3121
Webhttps://purple-biotech.com

Purple Biotech Management Efficiency

The company has return on total asset (ROA) of (0.2264) % which means that it has lost $0.2264 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3879) %, meaning that it generated substantial loss on money invested by shareholders. Purple Biotech's management efficiency ratios could be used to measure how well Purple Biotech manages its routine affairs as well as how well it operates its assets and liabilities.
Purple Biotech has accumulated 804 K in total debt with debt to equity ratio (D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. Purple Biotech has a current ratio of 14.01, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Purple Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Purple Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Purple Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Purple to invest in growth at high rates of return. When we think about Purple Biotech's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Ofer CPAEvogene
57
Pr MDEnlivex Therapeutics
67
Sangwoo LeeEnlivex Therapeutics
47
Eyal RonenEvogene
N/A
Shiran ManorClal Biotechnology Industries
N/A
Brian SchwartzEnlivex Therapeutics
57
Liron MBABioLine RX
N/A
CPA MBABioLine RX
62
, MBACompugen
52
Gil CPAPurple Biotech
57
Abi MDBioLine RX
47
Rivka SchwartzCompugen
N/A
Baruch HalpertEnlivex Therapeutics
52
Bertrand LiangPurple Biotech
60
CPA CPABioLine RX
47
Raziel FriedBioLine RX
N/A
Alberto SessaCompugen
61
Michael SchicklerPurple Biotech
65
Eran DorCompugen
N/A
Nir ArbelEvogene
43
Shai MBAEnlivex Therapeutics
57
Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs in the United States. Purple Biotech Ltd. was founded in 2010 and is headquartered in Rehovot, Israel. PURPLE BIOTECH operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 13 people. Purple Biotech (PPBT) is traded on Tel Aviv Stock Exchange in Israel and employs 5 people.

Management Performance

Purple Biotech Leadership Team

Elected by the shareholders, the Purple Biotech's board of directors comprises two types of representatives: Purple Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Purple. The board's role is to monitor Purple Biotech's management team and ensure that shareholders' interests are well served. Purple Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Purple Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
MA CPA, Chief Officer
Fabien Sebille, Chief Officer
Michael Schickler, Head Affairs
Ido Morpurgo, VP Operations
Nir Livneh, VP Affairs

Purple Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Purple Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Information and Resources on Investing in Purple Stock

When determining whether Purple Biotech is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Purple Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Purple Biotech Stock. Highlighted below are key reports to facilitate an investment decision about Purple Biotech Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Purple Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Purple Stock refer to our How to Trade Purple Stock guide.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Please note, there is a significant difference between Purple Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Purple Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Purple Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.